Terms: = Prostate cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4
107 results:
1. cdk12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
[TBL] [Abstract] [Full Text] [Related]
2. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic prostate cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of the Cyclin K-cdk12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
Frei K; Schecher S; Daher T; Hörner N; Richter J; Hildebrand U; Schindeldecker M; Witzel HR; Tsaur I; Porubsky S; Gaida MM; Roth W; Tagscherer KE
Int J Cancer; 2024 Mar; 154(6):1082-1096. PubMed ID: 37916780
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.
Fukushima T; Goto K; Hayashi T; Ikeda K; Hatayama T; Yamanaka R; Iwane K; Tasaka R; Kohada Y; Takemoto K; Kobatake K; Goriki A; Toshida A; Nakahara H; Motonaga M; Tokumo K; Fujii Y; Hayes CN; Okamoto W; Kubo T; Matsumoto T; Shiota M; Yamamoto N; Urabe Y; Hiyama E; Arihiro K; Hinoi T; Hinata N
Jpn J Clin Oncol; 2024 Feb; 54(2):175-181. PubMed ID: 37899139
[TBL] [Abstract] [Full Text] [Related]
5. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract] [Full Text] [Related]
6. cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine.
Nurminen A; Jaatinen S; Taavitsainen S; Högnäs G; Lesluyes T; Ansari-Pour N; Tolonen T; Haase K; Koskenalho A; Kankainen M; Jasu J; Rauhala H; Kesäniemi J; Nikupaavola T; Kujala P; Rinta-Kiikka I; Riikonen J; Kaipia A; Murtola T; Tammela TL; Visakorpi T; Nykter M; Wedge DC; Van Loo P; Bova GS
Genome Med; 2023 Oct; 15(1):82. PubMed ID: 37828555
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of Resistance to
Sartor O; Ledet E; Huang M; Schwartz J; Lieberman A; Lewis B; Layton J; Barata P; Jang A; Hawkins M; Pocha O; Lanka S; Harris K
J Nucl Med; 2023 Nov; 64(11):1721-1725. PubMed ID: 37770113
[No Abstract] [Full Text] [Related]
8. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant prostate cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract] [Full Text] [Related]
9. In Reply to "Pathogenic/Likely Pathogenic Somatic cdk12 Mutations in Black Men With prostate cancer".
Valle LF; Nickols NG; Yamoah K; Garraway IP; Maxwell KN; Lynch JA
Oncologist; 2023 Nov; 28(11):e1129-e1130. PubMed ID: 37706534
[TBL] [Abstract] [Full Text] [Related]
10. Pathogenic/Likely Pathogenic Somatic cdk12 Mutations in Black Men With prostate cancer.
Sartor O; Jang A; Ledet E
Oncologist; 2023 Nov; 28(11):e1127-e1128. PubMed ID: 37589230
[TBL] [Abstract] [Full Text] [Related]
11. Unique Spectrum of Activating BRAF Alterations in prostate cancer.
Chehrazi-Raffle A; Tukachinsky H; Toye E; Sivakumar S; Schrock AB; Bergom HE; Ebrahimi H; Pal S; Dorff T; Agarwal N; Mahal BA; Oxnard GR; Hwang J; Antonarakis ES
Clin Cancer Res; 2023 Oct; 29(19):3948-3957. PubMed ID: 37477913
[TBL] [Abstract] [Full Text] [Related]
12. Somatic and Germline Variants Affect Prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
13. Rucaparib for the Treatment of Metastatic Castration-resistant prostate cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
Jang A; Lanka SM; Huang M; Casado CV; Caputo SA; Sweeney PL; Gupta K; Pocha O; Habibian N; Hawkins ME; Lieberman AD; Schwartz J; Jaeger EB; Miller PJ; Layton JL; Barata PC; Lewis BE; Ledet EM; Sartor O
Prostate; 2023 Aug; 83(11):1028-1034. PubMed ID: 37113064
[TBL] [Abstract] [Full Text] [Related]
15. Molecular basis and therapeutic targets in prostate cancer: A comprehensive review.
Militaru FC; Militaru V; Crisan N; Bocsan IC; Udrea AA; Catana A; Kutasi E; Militaru MS
Biomol Biomed; 2023 Sep; 23(5):760-771. PubMed ID: 37021836
[TBL] [Abstract] [Full Text] [Related]
16. The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy.
Wang Y; Zhu Y; Fan L; Liu J; Pan J; Xue W
Int Urol Nephrol; 2023 Jun; 55(6):1447-1452. PubMed ID: 37017821
[TBL] [Abstract] [Full Text] [Related]
17. Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic prostate cancer.
Fei X; Du X; Gong Y; Liu J; Fan L; Wang J; Wang Y; Zhu Y; Pan J; Dong B; Xue W
Cancer Res Treat; 2023 Jul; 55(3):969-977. PubMed ID: 36915250
[TBL] [Abstract] [Full Text] [Related]
18. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract] [Full Text] [Related]
19. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
[TBL] [Abstract] [Full Text] [Related]
20. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant prostate cancer (mCRPC) with Bone Metastases (COMRADE).
Pan E; Xie W; Ajmera A; Araneta A; Jamieson C; Folefac E; Hussain A; Kyriakopoulos CE; Olson A; Parikh M; Parikh R; Saraiya B; Ivy SP; Van Allen EM; Lindeman NI; Kochupurakkal BS; Shapiro GI; McKay RR
Mol Cancer Ther; 2023 Apr; 22(4):511-518. PubMed ID: 36780008
[TBL] [Abstract] [Full Text] [Related]
[Next]